RHODES PHARMS
GenericsRHODES PHARMS is a generic drug manufacturer focused on Immunology, Infectious Disease, Metabolic. Key products include APTENSIO XR.
RHODES PHARMS's Key Drugs
RHODES PHARMS's core commercial portfolio centers on BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, APTENSIO XR, BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, spanning Immunology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
RHODES PHARMS's Recent FDA Approvals
New NDA/BLA approvals for RHODES PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
RHODES PHARMS's Therapeutic Areas
RHODES PHARMS's approved drugs and pipeline span 5 therapeutic areas, led by Immunology and Infectious Disease, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
RHODES PHARMS's Top Competitors
RHODES PHARMS's closest competitors by therapeutic-area and drug-target overlap include Merck, GSK, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
RHODES PHARMS Pipeline Snapshot
Active clinical trials for RHODES PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (3)
Discontinued (0)
Company Info
- First Approval
- 1988-02-10
- Latest
- 2026-06-18
- Applications
- 31